Literature DB >> 7539891

A cystic fibrosis mutation associated with mild lung disease.

K H Gan1, H J Veeze, A M van den Ouweland, D J Halley, H Scheffer, A van der Hout, S E Overbeek, J C de Jongste, W Bakker, H G Heijerman.   

Abstract

BACKGROUND: Cystic fibrosis is the most common lethal autosomal recessive disorder among whites. Among Dutch patients with cystic fibrosis, delta F508 is the most common mutation and A455E the second most common mutation of the cystic fibrosis transmembrane conductance regulator gene on chromosome 7. A455E is associated with preserved pancreatic function and residual secretion of chloride across membranes. We investigated whether it is also associated with less severe pulmonary disease in patients with cystic fibrosis.
METHODS: A total of 33 patients with compound heterozygosity for the A455E mutation were matched according to age and sex with patients who were homozygous for the delta F508 mutation. The pairs were analyzed with respect to the following outcome variables: age at diagnosis, pulmonary-function values, and the frequency of pseudomonas colonization, pancreatic sufficiency, and diabetes mellitus.
RESULTS: Cystic fibrosis was diagnosed at a later age in the patients with the A455E mutation than in the delta F508 homozygotes (mean age at diagnosis, 15.0 vs. 3.1 years; P < 0.001). Fewer patients with the A455E mutation had pancreatic insufficiency (21.2 percent vs. 93.9 percent, P < 0.001), and none had diabetes mellitus (0 percent vs. 27.3 percent, P = 0.004). Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) were significantly higher in the patients with the A455E mutation (mean FEV1, 73.9 percent of the predicted value vs. 54.3 percent of the predicted value; P = 0.002; mean FVC, 88.7 percent of the predicted value vs. 76.3 percent of the predicted value; P = 0.04). Fewer patients with the A455E mutation were colonized with Pseudomonas aeruginosa (33.3 percent vs. 60.6 percent, P = 0.02).
CONCLUSIONS: A455E is a common mutation causing cystic fibrosis in the Netherlands. Although several mutations are known to be associated with less severe pancreatic disease, our findings demonstrate a correlation between the A455E mutation and mild pulmonary disease. Because mortality in this disease depends primarily on the progression of pulmonary disease, patients with the A455E mutation have a better prognosis than patients who are homozygous for the delta F508 mutation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7539891     DOI: 10.1056/NEJM199507133330204

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  15 in total

Review 1.  Atypical cystic fibrosis--diagnostic and management dilemmas.

Authors:  Colin Wallis
Journal:  J R Soc Med       Date:  2003       Impact factor: 5.344

Review 2.  New therapeutic approaches for cystic fibrosis lung disease.

Authors:  Jane C Davies
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

Review 3.  Cystic fibrosis therapy--where we are and how we got there.

Authors:  D C Gruenert
Journal:  West J Med       Date:  1996-04

Review 4.  Gene therapy for cystic fibrosis: challenges and future directions.

Authors:  J M Wilson
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

5.  Genotype-phenotype correlation for pulmonary function in cystic fibrosis.

Authors:  J de Gracia; F Mata; A Alvarez; T Casals; S Gatner; M Vendrell; D de la Rosa; L Guarner; E Hermosilla
Journal:  Thorax       Date:  2005-07       Impact factor: 9.139

Review 6.  Cystic fibrosis chronic rhinosinusitis: a comprehensive review.

Authors:  Mohamad R Chaaban; Alexandra Kejner; Steven M Rowe; Bradford A Woodworth
Journal:  Am J Rhinol Allergy       Date:  2013 Sep-Oct       Impact factor: 2.467

Review 7.  Cystic fibrosis genetics: from molecular understanding to clinical application.

Authors:  Garry R Cutting
Journal:  Nat Rev Genet       Date:  2014-11-18       Impact factor: 53.242

Review 8.  Modifier genes in Mendelian disorders: the example of cystic fibrosis.

Authors:  Garry R Cutting
Journal:  Ann N Y Acad Sci       Date:  2010-12       Impact factor: 5.691

9.  Variants in the glutamate-cysteine-ligase gene are associated with cystic fibrosis lung disease.

Authors:  Edward F McKone; Jing Shao; Daisy D Frangolias; Cassie L Keener; Cynthia A Shephard; Federico M Farin; Mark R Tonelli; Peter D Pare; Andrew J Sandford; Moira L Aitken; Terrance J Kavanagh
Journal:  Am J Respir Crit Care Med       Date:  2006-05-11       Impact factor: 21.405

10.  Assessing the Disease-Liability of Mutations in CFTR.

Authors:  Claude Ferec; Garry R Cutting
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.